Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares increased 2.34 percent to close at $10.04 a share Tuesday. The stock traded between $9.32 and $10.24 on volume of 2.02 million shares traded. Analysts at Wells Fargo have recently downgraded the company’s rating to “market perform” from “outperform”. Shares of BioCryst Pharmaceuticals have gained over 500.0 percent in the past year.
Find out more about BioCryst Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/BCRX
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) shares increased 11.16 percent to close at $33.27 a share Tuesday. The stock traded between $30.43 and $33.74 on volume of 437,235 shares traded. Analysts at RW Baird have recently initiated coverage on the company with an “outperform” rating and a price target of $41.00. Shares of Enanta Pharmaceuticals have gained approximately 65 percent in the past year.
Find out more about Enanta Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/ENTA
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) shares surged 17.03 percent to close at $8.04 a share Tuesday. The stock traded between $6.89 and $8.11 on volume of 3.32 million shares traded. Analysts at JMP Securities have recently downgraded the company’s rating to “underperform” from “market perform”. Shares of Idenix Pharmaceuticals have gained approximately 70.0 percent in the past year.
Find out more about Idenix Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/IDIX
Raptor Pharmaceutical Corp. (NASDAQ: RPTP) shares increased 1.95 percent to close at $15.68 a share Tuesday. The stock traded between $14.88 and $16.10 on volume of 1.46 million shares traded. Analysts at Empire Asset have recently initiated coverage on the company with a “sell” rating and a price target of $8.00. Shares of Raptor Pharmaceutical have gained approximately 190.0 percent in the past year.
Find out more about Raptor Pharmaceutical including full access to the free equity report at:
www.RDInvesting.com/RPTP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]